| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 14, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Jeff Needham, Perrigo's Executive Vice President and President, Consumer Healthcare Americas, will present at the Oppenheimer 2017...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the "Early Tender Deadline") for...
-
Jun 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the forthcoming retirement of Chief Executive Officer John T....
-
Jun 2, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo CEO John T. Hendrickson will present at the Jefferies 2017 Healthcare Conference at 3:00 PM EDT on Tuesday, June 6, 2017....
-
May 31, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today that it and Perrigo Finance Unlimited Company, its wholly-owned finance subsidiary ("Perrigo Finance"), have...
-
May 30, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Wednesday, May 31 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer,...
-
May 30, 2017
Delivered first quarter 2017 GAAP ("reported") net sales of $1.2 billion, led by consumer-facing businesses net sales of $958 million Realized first quarter reported net income of $72 million and...
-
May 22, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Tuesday, May 23 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer, to...
-
May 22, 2017
Comprehensive Form 10-K reflects accounting treatment of historical Tysabri® royalty stream as a financial asset No impact on net cash flows or previously closed sale of Tysabri® Revised...
-
May 8, 2017New Directors Nominated by Starboard in Accordance With Previously Announced Agreement
Perrigo Company plc (NYSE; TASE: PRGO) today announced the appointment of Rolf A. Classon and Adriana Karaboutis to the Company's Board of Directors. Pursuant to the agreement with Starboard Value...
-
May 3, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on June 13, 2017 to shareholders of record on May 26, 2017.
-
May 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that search warrants were executed at the Company's corporate offices associated with an ongoing investigation by the U.S. Department of...
-
Apr 25, 2017- Tysabri® historical royalty stream determined to be a financial asset; Company to file 2016 Form 10-K, including restated fiscal 2014, fiscal 2015 and transition period 2015 audited financials and certain quarterly financial information as soon as practical
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today announced that the Company's Board of Directors, after consultation with management...
-
Mar 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has completed the divestiture of its rights to the royalty stream...
-
Mar 16, 2017- Continues to work with independent auditor, and expects to file its Form 10-K as soon as practical
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "We continue to make progress with our independent auditor, Ernst & Young...
-
Mar 8, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the first-to-market launch of the over-the-counter ("OTC") store brand equivalent to Women's Rogaine® 5% minoxidil foam (minoxidil topical...
-
Mar 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "As previously discussed, in connection with a review for the announced...
-
Mar 1, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application referencing Eli Lilly and...
-
Feb 27, 2017
Delivered preliminary unaudited calendar year 2016 record reported net sales of $5.6 billion and adjusted net sales of $5.5 billion Unaudited calendar year 2016 preliminary reported loss per...
-
Feb 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has signed a definitive agreement to divest its rights to the...
-
Feb 27, 2017Appoints Ron Winowiecki as Acting CFO Following Resignation of Judy L. Brown
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ron Winowiecki, Senior Vice President, Business Finance, has...
-
Feb 21, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on March 21, 2017 to shareholders of record on March 3,...
-
Feb 17, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral...
-
Feb 14, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, 2017 at approximately 4:00 p.m....
-
Feb 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for clindamycin, benzoyl peroxide...